STOCK TITAN

Treace Medical Concepts (TMCI) Stock News, Apr-Sep 2024

TMCI NASDAQ

Treace Medical Concepts, Inc. develops and markets orthopaedic medical devices for the surgical treatment of bunions and related midfoot deformities. Its updates center on the Lapiplasty® 3D Bunion Correction procedure and related technologies used by surgeons, ambulatory surgery centers and hospitals.

Recurring news themes for TMCI include quarterly and annual financial results, revenue guidance, surgeon adoption, cash and liquidity updates, product introductions and clinical data. Company announcements also cover additions to the bunion and midfoot technology portfolio, including SuperBite™ Compression Screw System, Lapiplasty® Lightning™ technology, SpeedMTP® and IntelliGuide® PSI, as well as patent portfolio activity and presentations at foot and ankle surgery conferences.

Rhea-AI Summary

Treace Medical Concepts (NASDAQ: TMCI) will showcase new product innovations and present updated clinical data at the American Orthopaedic Foot & Ankle Society Annual Meeting 2024. The company will highlight:

  • Nanoplasty™ MIS 3D Osteotomy System for minimally invasive bunion correction
  • IntelliGuide™ PSI Cut Guides for personalized surgical planning
  • Mini-Adductoplasty™ Guides for less-invasive midfoot correction
  • New SpeedPlate™ innovations for midfoot and rearfoot fusion
  • Micro-Lapiplasty™ Minimally Invasive System for small incision procedures

The company will also present interim data from the ALIGN3D™ and Mini3D™ Lapiplasty® clinical studies, demonstrating sustained positive outcomes at 3-4 years and 1-2 years post-procedure, respectively.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
-
Rhea-AI Summary

Treace Medical Concepts, Inc. (TMCI), a medical technology company specializing in bunion and midfoot deformity treatments, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. The company's CEO, John T. Treace, and CFO, Mark L. Hair, will engage in a fireside chat on September 5, 2024, at 10:00 am ET.

Investors can access a live webcast and replay of the event through Treace's investor relations website. The company encourages stakeholders to regularly check their website for important updates and information.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.55%
Tags
none
-
Rhea-AI Summary

Treace Medical Concepts (NASDAQ: TMCI) reported its Q2 2024 financial results, showing revenue growth of 6% to $44.5 million compared to Q2 2023. The company's gross margin was 80.2%, slightly down from 81.7% in the previous year. Despite revenue growth, Treace faced a net loss of $21.2 million, or ($0.34) per share, wider than the $12.3 million loss in Q2 2023. The increased loss was attributed to higher operating expenses, which rose to $57.1 million from $47.3 million year-over-year. Treace maintains a strong cash position of $97.0 million and reaffirmed its full-year 2024 revenue guidance of $201-$211 million, representing 7-13% growth. The company expects Adjusted EBITDA to improve by approximately 50% compared to 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.40%
Tags
Rhea-AI Summary

Treace Medical Concepts, Inc. (NASDAQ: TMCI), a medical technology company specializing in bunion and midfoot deformity treatments, has announced its plans to release second quarter 2024 financial results on August 6, 2024, after market close. The company will host a conference call at 4:30 pm ET to discuss the results. Investors can register to participate in the call and receive dial-in information. A live and archived webcast will be available on the company's investor relations website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
conferences earnings
-
Rhea-AI Summary

Treace Medical Concepts announced its participation in the Truist Securities MedTech Conference on June 18, 2024, at 8:00 am Eastern Time. CEO John T. Treace and CFO Mark L. Hair will join a fireside chat during the event. The discussion will be webcasted live and available for replay on Treace's investor relations website. Treace, known for its Lapiplasty® and Adductoplasty® Procedures, spearheads advancements in the surgical treatment of bunions and midfoot deformities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
conferences
-
Rhea-AI Summary

Treace Medical Concepts, Inc. reported $51.1 million in revenue for Q1 2024, a 21% increase from the same period in 2023. Despite a net loss and revised guidance for 2024, the company achieved milestones, expanded its patent portfolio, and introduced new technologies. The CEO remains optimistic about navigating competitive challenges and delivering shareholder value.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-62.50%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.75%
Tags
none
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.13%
Tags
conferences
-
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.95%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.80%
Tags
conferences earnings

FAQ

What is the current stock price of Treace Medical Concepts (TMCI)?

Treace Medical Concepts (TMCI) last closed at $4.35.

What is the market cap of Treace Medical Concepts (TMCI)?

The market cap of Treace Medical Concepts (TMCI) is approximately $285.2M.